All News

The FDA’s decision means that oncologists can use FoundationOne Liquid CDx to identify patients with ROS1-positive non–small cell lung cancer or NTRK fusion–positive solid tumors who are eligible for treatment with entrectinib.

Bringing clinical cancer research to the community setting could offer better accessibility and lower costs without sacrificing quality of care.

The blood test is intended for use in detecting a range of cancers—including liver and lung cancer—among adults ages 50 to 75 years.

The TriNetra™-Glio liquid biopsy has received breakthrough device designation from the FDA for the diagnosis of brain tumors.

“It’s a wonderful time to work in the field of myeloma. There’s so much progress being made. Given how much we’ve accomplished in the last 5 years, I can only imagine what the next 5 will hold.”

The Japanese approval of acalabrutinib for the treatment of patients with treatment-naïve chronic lymphocytic leukemia was supported by data from the phase 3 ELEVATE-TN trial.

The decision to approve durvalumab plus tremelimumab in Japan for patients with advanced non–small cell lung cancer and unresectable biliary tract cancer and liver cancer was based on data from several phase 3 studies.

The presence of several risk factors—such as age, race and mutation status—for contralateral breast cancer must be considered when making treatment decisions, according to an expert from the Mayo Clinic.

A triplet, PDS0101-based combination regimen enhanced survival across several types of HPV-positive cancer, according to interim data from a phase 2 trial.

The biologic license application for toripalimab plus chemotherapy for the treatment of recurrent or metastatic nasopharyngeal carcinoma is expected to be resubmitted by mid-summer 2023.

The phase 3 NEPTUNE study indicated that durvalumab plus tremelimumab did not reach an amended primary end point of improved overall survival among patients with metastatic non–small cell lung cancer with a blood tumor mutational burden of at least 20 mut/Mb, though the combination did yield a numerical reduction in risk of death.

Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.

“You have to be on your game continually, you have to continually self-evaluate, and the field moves quickly.”

Data from the phase 1/2 CodeBreaK 100 trial indicated that 84% of patients with KRAS G12C-mutated pancreatic cancer treated with sotorasib experienced disease control.

An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.

Durvalumab plus tremelimumab has been recommended for approval in the European Union for treatment of advanced liver and lung cancers.

Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.

Topline results from the phase 3 GLOW trial indicated that zolbetuximab plus CAPOX yielded a statistically significant increase in progression-free survival over placebo/CAPOX.

The study’s lead author explained that using rezafungin may avoid some of the negative drug interactions associated with other anti-fungal drugs in patients with cancer.

Data presented at this year’s American Society of Hematology Annual Meeting spotlight promising novel treatment options for acute myeloid leukemia, according to an expert from The University of Texas MD Anderson Cancer Center.

An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.

Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.

Findings from the phase 3 NORA study identified a numerically longer median overall survival among patients with platinum-sensitive recurrent ovarian cancer treated with maintenance niraparib regardless of BRCA mutation status.

18F-sodium fluoride PET-CT appeared to be a more accurate identifier of bone metastases in patients with breast and prostate cancer than the standard SPECT method.

Future research must address ways to improve the prediction of kidney cancer recurrence to better inform patients, says an expert from the Royal Free London NHS Foundation Trust.

Data from the phase 3 PEARL trial indicated that durvalumab yielded a clinically significant improvement in overall survival but did not meet statistical significance among patients with stage IV non–small cell lung cancer with high PD-L1 expression.

Positive topline data from the phase 2b HERIZON-BTC-01 trial indicate zanidatamab may improve outcomes for patients with HER2-amplified and expressing biliary tract cancers.

Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.

Olaparib in combination with abiraterone and prednisone or prednisolone alone has been approved as treatment for metastatic castration-resistant prostate cancer in the European Union.

Treatment with the BTK inhibitor ibrutinib plus the CAR-T cell therapy tisagenlecleucel produced a high rate of durable responses in patients with relapsed/refractory mantle cell lymphoma after they stopped treatment at 6 months, according to early data from the TARMAC trial.